Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: Cost effectiveness and risk sharing

PharmacoEconomics

Volumn 24, Issue 9, 2006, Pages 903-915

  Wlodarczyk, John H ^a,h   Cleland, Leslie G ^b   Keogh, Anne M ^c   McNeil, Keith D ^d   Perl, Kate ^e   Weintraub, Robert G ^f   Williams, Trevor J ^g  

^a John Wlodarczyk Consulting Services   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e Nitecs Pty Limited   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; DILTIAZEM; FUROSEMIDE; PROSTACYCLIN; SPIRONOLACTONE; WARFARIN;

ARTICLE; AUSTRALIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG USE; FUNDING; HEALTH CARE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGISTER; RISK MANAGEMENT; SENSITIVITY ANALYSIS;

ANTIHYPERTENSIVE AGENTS; AUSTRALIA; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FINANCING, GOVERNMENT; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; MODELS, ECONOMIC; REGISTRIES; RISK SHARING, FINANCIAL; SULFONAMIDES; SURVIVAL RATE;

EID: 33748347529     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624090-00007     Document Type: Article

References (38)

1. Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104 (1): 236-50
2. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12): 896-903
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115 (5): 343-9
4. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35 (10): 989-93
5. Sulica R, Poon M. Current medical treatment of pulmonary artery hypertension. Mt Sinai J Med 2004; 71 (2): 103-14
6. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358 (9288): 1119-23
7. McLaughlin V, Sitbon O, Rubin L, et al. The effect of first line bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003; 167 (7): A441
8. Highland KB, Strange C, Mazur J, et al. Treatment of pulmonary arterial hypertension. Chest 2003; 124 (6): 2087-92
9. Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical benefits advisory committee. Canberra (ACT): Comm Dept of Health and Ageing, 2002
10. Therapeutic Goods Administration. Drugs designated as orphan drugs [online]. Available from URL: http://www.health.gov.au/tga/docs/html/orphand2. htm [Accessed 2005 Dec 4]
11. Commonwealth Department of Health and Ageing. The orphan drug programme and improving community access to effective drugs for rare diseases. Canberra (ACT): Comm Dept of Health and Ageing, 2001
12. Pharmaceutical Benefits Advisory Committee. Other relevant factors and the "rule of rescue" [online]. Available from URL: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ health-pbs-general-pubs-pharmpac-relevant.htm-copy3 [Accessed 2005 Apr 3]
13. Hadorn DC. The Oregon priority-setting exercise: quality of life and public policy. Hastings Cent Rep 1991; 21 (3): S11-6
14. Conner L. The rule of rescue. Ala Med 1991; 60 (10): 2, 5-6
15. Roux S, Kobrin I, Rainisio M, et al. Long-term open-label study in patients with pulmonary hypertension who participated in controlled clinical studies with bosentan (interim study report - protocol AC-052-354). Actelion Pharmaceuticals US, Inc., 2001 Oct 3
16. Therapeutic Guidelines Ltd. Cardiovascular. In. Version 4 ed. Melbourne (SA): Therapeutic Guidelines Ltd, 2003: Pulmonary Hypertension Section
17. Medicare Australia. Physician's guide: a guide to prescribing bosentan monohydrate and iloprost trometamol within the PBS section 100 of the National Health Act 1953: restriction criteria [online]. Available from URL: http://www.medicareaustralia.gov.au/resources/pbs/ ma_physician_guide_bosentan_and_iloprost_011005.pdf [Accessed 2006 Mar 3]
18. Commonwealth of Australia. Bosentan monohydrate. In: Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Fyshwick (ACT): National Capital Printing, 2004: 309-18
19. Keogh A, MacDonald P, Williams T, et al. Tracleer (bosentan), a dual endothelin receptor antagonist (ERA), for the treatment of pulmonary arterial hypertension (PAH): interim results of an Australian multicentre study. Cardiac Society of Australia and New Zealand (CSANZ) Congress; 2003 Aug 10-13; Adelaide (SA)
20. Policy Analysis Inc. Exploratory analyses of data from BREATHE-1 on measures of potential pharmacoeconomic significance. Brookline (MA): Policy Analysis Inc., 2001
21. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89 (4): 1733-44
22. Kapoor A, Sheppard R, Panyon J, et al. Clinical outcome comparison in pulmonary artery hypertension patients treated with epoprostenol and bosentan [poster]. American Heart Association Scientific Sessions; 2003 Nov 9-12; Orlando (FL)
23. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25 (2): 244-9
24. AHTAC. Superspecialty service guidelines for lung transplantation services. Canberra (ACT): Australian Health Technology Advisory Committee, 1998
25. Mendeloff EN, Meyers BF, Sundt TM, et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 2002; 73: 209-19
26. Keogh A, Wlodarczyk J. Idiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QoL on bosentan. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4 (5): 505-13
27. Schedule of Pharmaceutical Benefits. Fyshwick (ACT): Australian Government, Department of Health and Ageing, 2002 Aug
28. Medicare Benefits Schedule. Fyshwick (ACT): Australian Government, Department of Health and Ageing, 2001 Nov
29. NHCDC. Australian refined diagnosis related groups [AR-DRG]. Canberra (ACT): Commonwealth of Australia, 1999-2000
30. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-15
31. Zolessi R. Epoprostenol (Flolan®). J Pharmacy Society Wisconsin 2001 Nov/Dec: 25-9
32. Keogh A, Macdonald P, Williams T, et al. Tracleer (bosentan), for the treatment of pulmonary arterial hypertension (PAH): six month quality of life data [abstract]. J Heart Lung Transplant 2004; 23 (2S): S54
33. Keogh A, Wlodarczyk J. Idiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QoL on bosentan. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4 (5): 505-13
34. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Haemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50
35. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-208
36. Commonwealth Department of Health and Ageing. Schedule of pharmaceutical benefits. Fyshwick (ACT): National Capital Printing, 2005
37. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19 (11): 1103-9
38. Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003; 326: 388-92